Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mechanistic insights into immune related toxicities in subjects with relapsed/ refractory follicular lymphoma treated with zandelisib
    Meeting Abstract

    Sasi, B. K.; Martindale, S. P.; Shupe, S. J.; Fernandes, S. M.; Yadav, S.; Machado, J. H.; Phillips, T.; Zelenetz, A. D.; Brown, J. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of single-agent zandelisib administered by intermittent dosing in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Final results of the tidal phase 2 study
    Meeting Abstract

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K. M.; Collins, G. P.; Bishton, M.; López Jiménez, J.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • High-resolution single cell T-cell phenotyping of B-cell lineage lymphomas reveals unique immune signatures and potential targetable vulnerabilities
    Meeting Abstract

    El Daker, S.; Baik, J.; Dogan, A.; Zhu, M.; Roshal, M.; Galera, P. K.
    Blood (2022)

    Fulltext@MSK | Save
  • "Big Boom" (4 Gy x 1) radiation treatment (RT) versus "Big Boom" (2 Gy x 2) for non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Hajj, C.; Lebow, E. S.; Lee, J.; Fregonese, B.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K. R.; Freret, M. E.; Imber, B. S.; Yahalom, J.
    Blood (2022)

    Fulltext@MSK | Save
  • Updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of brexucabtagene autoleucel (KTE-X19) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
    Meeting Abstract

    Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy
    Meeting Abstract

    Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage
    Meeting Abstract

    Vekariya, U. M.; Sullivan-Reed, K.; Toma, M.; Nieborowska-Skorska, M.; Le, B. V.; Caron, M. C.; Kukuyan, A. M.; Podszywalow-Bartnicka, P.; Chitrala, K.; Atkins, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • RNA deadenylation subunit CNOT3 promotes myeloid leukemia by driving translation of oncogenic targets
    Meeting Abstract

    Ghashghaei, M.; Yue, M.; Arsalan, A.; Bombaci, G.; Miko, S. S.; Shaalan, H.; Edin, G.; Morin, G.; Perna, F.; Vu, L. P.
    Blood (2022)

    Fulltext@MSK | Save
  • Fructose treatment targets myeloid leukemogenesis in IDH2 mutants by exhausting alpha-ketoglutarate pools
    Meeting Abstract

    Savino, A. M.; Turner, B.; Jeong, S.; Schild, T.; Yang, X.; Luo, H.; Chirayil, R.; Cullen, Q.; Chan, M.; Han, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The characteristics and prognosis of patients with clonal cytopenias of undetermined significance, including cancer and therapy-related clonal cytopenias
    Meeting Abstract

    Xie, Z.; Smith, A.; Komrokji, R. S.; Al Ali, N.; Patel, A. A.; Saygin, C.; Zeidan, A. M.; Bewersdorf, J. P.; Kishtagari, A.; Zeidner, J. F.; more...
    Blood (2022)

    Fulltext@MSK | Save